Literature DB >> 22249840

Skepticism about thrombolytics in stroke is not unreasonable.

Ryan P Radecki.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22249840     DOI： 10.1038/nrneurol.2011.89-c1

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  12 in total

1.  Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

Authors:  W M Clark; S Wissman; G W Albers; J H Jhamandas; K P Madden; S Hamilton
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.

Authors:  I L Katzan; A J Furlan; L E Lloyd; J I Frank; D L Harper; J A Hinchey; J P Hammel; A Qu; C A Sila
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

Review 3.  Thrombolysis after acute myocardial infarction.

Authors:  P A Nee
Journal:  J Accid Emerg Med       Date:  1997-01

4.  Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.

Authors:  G A Donnan; S M Davis; B R Chambers; P C Gates; G J Hankey; J J McNeil; D Rosen; E G Stewart-Wynne; R R Tuck
Journal:  JAMA       Date:  1996-09-25       Impact factor: 56.272

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

7.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

8.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

9.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

10.  Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group.

Authors: 
Journal:  Lancet       Date:  1995-12-09       Impact factor: 79.321
View more
  2 in total

1.  What Drives Greater Assimilation of Telestroke in Emergency Departments?

Authors:  Lori Uscher-Pines; Jessica Sousa; Kori Zachrison; Amy Guzik; Lee Schwamm; Ateev Mehrotra
Journal:  J Stroke Cerebrovasc Dis       Date:  2020-09-20       Impact factor: 2.136

2.  tPA for Acute Ischemic Stroke and Its Controversies: A Review.

Authors:  Brian Dewar; Michel Shamy
Journal:  Neurohospitalist       Date:  2019-04-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.